Welcome to our dedicated page for Regen Biopharma SEC filings (Ticker: RGBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech narratives rarely fit neatly into standard forms, and Regen Biopharma’s disclosures are no exception. When investors search for “Regen Biopharma SEC filings explained simply,” they’re usually wrestling with patent-heavy language, variable R&D costs, and dilution risk buried deep in a 10-K. Tracking “Regen Biopharma insider trading Form 4 transactions” or learning whether new immunotherapy data moved into IND-enabling studies demands hours—time most analysts don’t have.
Stock Titan solves that challenge with AI-powered summaries, tagging the exact section you need in seconds. Our platform delivers:
- Track “Regen Biopharma executive stock transactions Form 4” alongside peer biotech benchmarks.
- Monitor “Regen Biopharma Form 4 insider transactions real-time” and receive instant alerts.
- Dive into each “Regen Biopharma quarterly earnings report 10-Q filing” in plain English with KPI callouts.
- Open the “Regen Biopharma annual report 10-K simplified” to see pipeline milestones, cash runway, and licensing assumptions.
- Scan the “Regen Biopharma proxy statement executive compensation” tables without scrolling through appendices.
- Get “Regen Biopharma 8-K material events explained” minutes after they hit EDGAR.
Whether you’re modeling cash burn or validating catalysts, “understanding Regen Biopharma SEC documents with AI” means seeing beyond raw PDFs. Our AI highlights grant income trends, flags dilution clauses, and pairs every disclosure with context-rich charts. Add “Regen Biopharma earnings report filing analysis” to your workflow and compare quarter-over-quarter R&D spending, insider behavior, and pipeline progress—without decoding biotech jargon yourself.
Regen BioPharma, Inc. filed an 8‑K disclosing unregistered sales of common stock. The company issued 6,800,000 shares on October 8, 2025 for $68,000 under a Tier 2 Regulation A offering sold directly by management.
On October 27, 2025, it issued 3,500,000 shares for $35,000 via Tier 2 Regulation A, and separately issued 4,500,000 shares to satisfy $30,204 of principal and $13,536 of accrued interest on convertible indebtedness under Section 4(a)(2), with no underwriters, commissions, or general solicitation.
On October 28, 2025, Regen issued 7,100,000 shares for $71,000 via Tier 2 Regulation A, and on November 10, 2025, it issued 1,780,000 shares for $17,800 via Tier 2 Regulation A. All Tier 2 Regulation A sales were conducted directly through management.
FAQ
What is the current stock price of Regen Biopharma (RGBP)?
What is the market cap of Regen Biopharma (RGBP)?
